↓ Skip to main content

Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada

Overview of attention for article published in Allergy, Asthma & Clinical Immunology, December 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#46 of 924)
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news
6 news outlets

Readers on

mendeley
3 Mendeley